Qfitlia (fitusiran), an RNAi therapy for Hemophilia A or B, is now available nationwide through Prodigy Health.

Prodigy Health’s specialty portfolio now includes Pfizer’s biosimilars—expanding access to high-quality, cost-effective treatments across oncology, immunology, hematology, and supportive care.

Prodigy Health is proud to offer Alhemo (concizumab), a newly approved, cutting-edge subcutaneous therapy for hemophilia A or B with inhibitors.

Prodigy Health announces the availability of HYMPAVZI™ (marstacimab-hncq) by Pfizer, a groundbreaking once-weekly treatment for hemophilia A and B, reinforcing its commitment to advancing specialty pharmaceutical access with innovative, patient-centered solutions.

Prodigy Health appoints Edward Zhu, a seasoned financial strategist and Head of Private Credit at A-CAP, to its Board of Directors.

Prodigy Health appoints Jon Houssian as Executive Chairman.

Prodigy Health appoints Fei Li to its Board of Directors, leveraging her extensive expertise in private equity, investment banking, and strategic financial growth to drive innovation and expand its leadership in specialty pharmaceutical distribution.

Prodigy Health has secured a $6.5 million direct investment from A-CAP, expanded its asset-based loan facility with Gibraltar Business Capital to $30 million, and strengthened its Board of Directors with seasoned industry leaders, fueling its rapid growth and reinforcing its mission to revolutionize specialty pharmaceutical distribution.

Prodigy Health appoints Chris Ground to its Board of Advisors, leveraging his three decades of healthcare leadership and operational expertise to drive innovation and excellence in specialty pharmaceutical distribution.

Prodigy Health welcomes Newton Juhng to its Board of Directors, bringing extensive expertise in healthcare finance and investments to support the company’s innovation and growth in specialty pharmaceutical distribution.